VistaGen Therapeutics Valuation
Is VTGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VTGN?
Other financial metrics that can be useful for relative valuation.
|What is VTGN's n/a Ratio?|
Price to Book Ratio vs Peers
How does VTGN's PB Ratio compare to its peers?
|Company||PB||Estimated Growth||Market Cap|
SLS SELLAS Life Sciences Group
ADVM Adverum Biotechnologies
ORTX Orchard Therapeutics
VTGN VistaGen Therapeutics
Price to Earnings Ratio vs Industry
How does VTGN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price to Book Ratio vs Fair Ratio
What is VTGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.7x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate VTGN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of VTGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?